Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorGastromed-
Autor(es): dc.contributorUniversidade Estadual de Campinas (UNICAMP)-
Autor(es): dc.contributorUniversity of Vale Do Itajaí-
Autor(es): dc.contributorSanta Casa Sao Paulo Medical School-
Autor(es): dc.contributorFederal University of Juiz de Fora-
Autor(es): dc.contributorFeevale University-
Autor(es): dc.contributorHospital de Clínicas de Passo Fundo-
Autor(es): dc.contributorPasso Fundo University-
Autor(es): dc.contributorUniversity Cattholic PUC-RS Porto Alegre-
Autor(es): dc.contributorInflammatory Bowel Disease Center - DIIMUNO-
Autor(es): dc.contributorGastrosaúde Clinic-
Autor(es): dc.contributorFederal University of Rio de Janeiro-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorParra, Rogério Serafim-
Autor(es): dc.creatorde Sá Brito Fróes, Renata-
Autor(es): dc.creatorMagro, Daniela Oliveira-
Autor(es): dc.creatorda Costa Ferreira, Sandro-
Autor(es): dc.creatorde Mello, Munique Kurtz-
Autor(es): dc.creatorde Azevedo, Matheus Freitas Cardoso-
Autor(es): dc.creatorDamião, Aderson Omar Mourão Cintra-
Autor(es): dc.creatorde Sousa Carlos, Alexandre-
Autor(es): dc.creatorBarros, Luísa Leite-
Autor(es): dc.creatorde Miranda, Maria Luiza Queiroz-
Autor(es): dc.creatorVieira, Andrea-
Autor(es): dc.creatorSales, Marcos Paulo Moraes-
Autor(es): dc.creatorZabot, Gilmara Pandolfo-
Autor(es): dc.creatorCassol, Ornella Sari-
Autor(es): dc.creatorTiburcio Alves, Antonio José-
Autor(es): dc.creatorLubini, Márcio-
Autor(es): dc.creatorMachado, Marta Brenner-
Autor(es): dc.creatorFlores, Cristina-
Autor(es): dc.creatorTeixeira, Fabio Vieira-
Autor(es): dc.creatorCoy, Claudio Saddy Rodrigues-
Autor(es): dc.creatorZaltman, Cyrla-
Autor(es): dc.creatorChebli, Liliana Andrade-
Autor(es): dc.creatorSassaki, Ligia Yukie-
Autor(es): dc.creatorFéres, Omar-
Autor(es): dc.creatorChebli, Júlio Maria Fonseca-
Data de aceite: dc.date.accessioned2025-08-21T15:39:47Z-
Data de disponibilização: dc.date.available2025-08-21T15:39:47Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2025-11-30-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1186/s12876-025-03656-x-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/298676-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/298676-
Descrição: dc.descriptionAim: To assess the real-life, long-term effectiveness and safety of tofacitinib in a large cohort of patients with refractory or difficult-to-treat ulcerative colitis (UC). Methods: This multicenter, retrospective, observational cohort study included patients with moderately to severely active UC who received tofacitinib for at least 8 weeks. Clinical remission and response, endoscopic response and remission, biochemical response and remission, steroid-free clinical remission, primary and secondary loss of response, drug discontinuation, the need for dose optimization, the need for colectomy, and adverse events were evaluated over up to 30 months. Results: We included 127 patients with UC, with a mean age of 40.3 ± 14.2 years; 58.2% were male, 75.6% had pancolitis, and 79.5% had previously failed at least one biological therapy, predominantly anti-TNF agents (70.1%). Clinical remission was observed in 31.5% of patients at weeks 12–16, 46.5% at 26 ± 4 weeks, and 37.0% at 1 year. Steroid-free clinical remission was achieved in 28.6%, 44.8%, and 37.1% of patients at the same time points, respectively. Biochemical remission was achieved in 33.6% of patients at 26 ± 4 weeks and 29.3% at 1 year. Endoscopic response and endoscopic remission within 1 year were observed in 46.0% and 15.3% of patients, respectively. Ten patients (7.9%) required colectomy, and 13 patients (10.2%) required hospitalization, all of whom had been previously exposed to biologics. The colectomy rate was significantly greater in patients with serum albumin levels ≤ 3.5 g/dL (21.4% vs. 4.1%, p = 0.013). Conclusion: In this large, long-term real-world study involving patients with predominantly biologically refractory UC, tofacitinib effectively induced clinical remission and endoscopic improvement and prevented colectomy for more than 30 months, with a favorable safety profile. Notably, baseline hypoalbuminemia was associated with higher colectomy rates.-
Descrição: dc.descriptionDepartment of Surgery and Anatomy Ribeirão Preto Medical School University of São Paulo, São Paulo-
Descrição: dc.descriptionGastromed Department of Gastroenterology and Endoscopy-
Descrição: dc.descriptionDepartment of Surgery State University of Campinas (UNICAMP), SP-
Descrição: dc.descriptionDepartment of Medicine Ribeirão Preto Medical School University of São Paulo, São Paulo-
Descrição: dc.descriptionDepartment of Gastroenterology University of Vale Do Itajaí, Santa Catarina-
Descrição: dc.descriptionDepartment of Gastroenterology University of São Paulo School of Medicine-
Descrição: dc.descriptionDepartment of Internal Medicine Santa Casa Sao Paulo Medical School-
Descrição: dc.descriptionDivision of Gastroenterology Department of Medicine Inflammatory Bowel Disease Center Federal University of Juiz de Fora-
Descrição: dc.descriptionDepartment of Colon and Rectum Surgery Moinhos de Vento Hospital Feevale University-
Descrição: dc.descriptionDepartment of Colorectal Surgery Atitus Medical School Hospital de Clínicas de Passo Fundo, Rio Grande Do Sul-
Descrição: dc.descriptionDepartment of Surgery PUC-Campinas Medical School PUC-Campinas University, São Paulo-
Descrição: dc.descriptionPasso Fundo University, Rio Grande Do Sul-
Descrição: dc.descriptionDepartment of Gastroenterology University Cattholic PUC-RS Porto Alegre-
Descrição: dc.descriptionInflammatory Bowel Disease Center - DIIMUNO, Rio Grande Do Sul-
Descrição: dc.descriptionGastrosaúde Clinic, São Paulo-
Descrição: dc.descriptionDepartment of Internal Medicine School of Medicine Federal University of Rio de Janeiro-
Descrição: dc.descriptionDepartment of Internal Medicine Medical School São Paulo State University (Unesp), São Paulo State-
Descrição: dc.descriptionDepartment of Internal Medicine Medical School São Paulo State University (Unesp), São Paulo State-
Idioma: dc.languageen-
Relação: dc.relationBMC Gastroenterology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectInflammatory bowel disease-
Palavras-chave: dc.subjectJak inhibitors-
Palavras-chave: dc.subjectTofacitinib; Real-world-
Palavras-chave: dc.subjectUlcerative colitis-
Título: dc.titleTofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.